Vir Biotechnology, Inc. (VIR) Dividend History

Vir Biotechnology, Inc. is a biotechnology company focused on developing and commercializing innovative therapies to treat and prevent infectious diseases. Founded with a mission to enhance immune responses and improve healthcare outcomes, Vir leverages cutting-edge science in immunology and antibody technologies to address global health challenges, including viral infections such as influenza, HIV, and COVID-19.

1800 Owens Street, San Francisco, CA, 94158
Phone: 415-906-4324
Website: https://www.vir.bio
Dividend Yield: 2.29%
Dividend Frequency: Quarterly

Dividend History

Pay Date Amount Ex Dividend Date Record Date
December 03, 2010 $0.03 11/03/2010 11/05/2010
September 17, 2010 $0.03 08/25/2010 08/27/2010
June 11, 2010 $0.03 05/12/2010 05/14/2010
March 19, 2010 $0.03 03/03/2010 03/05/2010
December 01, 2009 $0.03 11/06/2009 11/10/2009
Show more

Dividends Summary

  • Vir Biotechnology, Inc. has issued 13 dividend payments over the past 3 years
  • The most recent dividend was paid 5374 days ago, on December 3, 2010
  • The first recorded dividend was paid on December 5, 2007
  • The highest dividend payout was $0.03 per share
  • The average dividend over this 3 year span is $0.03 per share

Company News

  • Vir (VIR) Q2 Revenue Drops 61%

    Vir Biotechnology reported a Q2 2025 net loss of $0.80 per share, with revenues of $1.2 million. The company advanced its clinical pipeline in hepatitis delta and oncology, maintaining $892.1 million in cash reserves while continuing to invest in research and development.

    The Motley Fool
    Featured Companies: ALNY
  • Biotech Stock Roundup: GSK's Litigation Update, BIIB's Drug Approval & Other Updates

    GSK and Biogen (BIIB) are in the spotlight following litigation updates and drug approval, respectively.

    Zacks Investment Research
    Featured Companies: AMGN BIIB VKTX
  • Evaluating Vir Biotechnology: Insights From 5 Financial Analysts

    Across the recent three months, 5 analysts have shared their insights on Vir Biotechnology (NASDAQ:VIR), expressing a variety of opinions spanning from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 1 0 0 Last 30D 1 0 0 0 0 1M Ago 2 0 1 0 0 2M Ago 0 0 0 0 0 3M Ago 1 0 0 0 0 Analysts have set 12-month price targets for Vir Biotechnology, revealing an average target of $71.4, a high estimate of $110.00, and a low estimate of $12.00. Witnessing a positive shift, the current average has risen by 614.0% from the previous average price target of $10.00. Deciphering Analyst Ratings: An In-Depth Analysis The analysis of recent analyst actions sheds light on the perception of Vir Biotechnology by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Patrick Trucchio HC Wainwright & Co. Maintains Buy $110.00 - Patrick Trucchio HC Wainwright & Co. Maintains Buy $110.00 - Eric Joseph JP Morgan Raises Neutral $12.00 $10.00 Joseph Stringer Needham Maintains Buy $15.00 - Patrick Trucchio HC Wainwright & Co. Maintains Buy $110.00 - Key Insights: Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to ...Full story available on Benzinga.com

    Benzinga
Page data last updated 08/19/2025 20:59:37 UTC Dividend yield is calculated using only dividends that have already been paid. Future or declared dividends are not included